BPC 157 Protects Against Organ Damage After Major Bowel Surgery in Rats

Wistar rats underwent massive small bowel resection with anastomosis creation. Immediately after surgery, rats were given intraperitoneal injections of diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg), alone or in combinations. Animals were assessed 24 hours later for anastomosis healing quality, intestinal adaptation, and macro/microscopic lesions in the gastrointestinal tract, liver, and brain (cerebrum, hippocampus, cerebellum).

Major bowel surgery carries significant risks of complications including anastomosis failure, organ damage, and impaired intestinal adaptation. NSAIDs like diclofenac, commonly used for post-surgical pain, can worsen these outcomes. BPC 157’s ability to protect multiple organ systems simultaneously — gut, liver, and brain — through what appears to involve the COX-NO system suggests it could be a valuable therapeutic agent for post-surgical recovery, particularly in situations where NSAID use is necessary.

This study is part of an extensive body of BPC 157 research from the Sikiric lab group, which has published numerous studies on this gastric pentadecapeptide’s wound-healing and protective properties. The finding that BPC 157 works across multiple organ systems and overcomes COX-NO system inhibition adds to the evidence for its broad cytoprotective mechanism. However, BPC 157 research remains predominantly preclinical, and human clinical trials are still limited.

This is an animal study with only a 24-hour follow-up period, which cannot predict long-term outcomes or human responses. The sample size per group is not specified in the abstract. The research comes from a single lab group (Sikiric et al.) that produces the majority of BPC 157 research, limiting independent replication. The mechanisms by which BPC 157 achieves such broad protective effects remain incompletely understood. No human surgical studies with BPC 157 exist.